Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in… (NCT00005104) | Clinical Trial Compass
CompletedNot Applicable
Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome
United States99 participantsStarted 2000-01
Plain-language summary
OBJECTIVES:
I. Determine whether reduction of serum insulin levels by metformin increases ovulatory response to clomiphene citrate in women with polycystic ovary syndrome.
Who can participate
Age range18 Years – 40 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Patients with chronic anovulation due to polycystic ovary syndrome (PCOS) who have failed clomiphene citrate
Must have oligoovulation and hyperandrogenemia
--Prior/Concurrent Therapy--
Endocrine therapy: At least 2 months since prior clomiphene citrate
Other:
* At least 2 months since prior standard therapy (including over the counter drugs)
* At least 2 months since prior investigational drugs
* Prior multi/prenatal vitamins allowed
--Patient Characteristics--
Hematopoietic: Hematocrit greater than 38%
Hepatic:
* Liver function normal
* No clinically significant hepatic disease
Renal:
* No clinically significant renal disease
* Creatinine less than 1.4 mg/dL
* No proteinuria
Cardiovascular: No clinically significant cardiac disease
Pulmonary: No clinically significant pulmonary disease
Hormonal:
* Thyroid function normal
* Prolactin normal
* Estradiol normal
* Fasting 17 alpha-hydroxy progesterone less than 200 ng/dL OR No late onset adrenal hyperplasia 21 alpha-hydroxylase deficiency
Other:
* Not pregnant
* Negative pregnancy test
* Male partner must have a normal semen analysis by WHO criteria
* Must be in acceptable health by interview, medical history, physical exam, and laboratory tests
* No diabetes mellitus
* No clinically significant neurologic, psychiatric, infectious, neoplastic, or metabolic disease
* No clinically significant malignant disease except nonmelanomatous skin cancer
* At least 1 y…
Trial details
NCT IDNCT00005104
SponsorNational Center for Research Resources (NCRR)